Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on serum uric acid in type 2 diabetes mellitus
ChiCTR2000040135Phase 4Recruiting
- Sponsor
- Weishan People's Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Weishan People's Hospital. Primary endpoint: serum uric acid. Started Jun 2020; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000040135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040135.